N1 Life, Inc.

N1 Life is a biotechnology company founded in 2019 that focuses on developing peptide-based and polymer-based delivery platforms to overcome biological barriers in drug and cosmetic delivery. Spun out of Stanford University, the company utilizes AI-designed peptides and targeted delivery systems, such as its Absotride peptide platform and ChARLS polymer delivery system, to improve the solubility, penetration, and targeted efficacy of therapeutic and skincare actives. By creating novel molecular delivery vectors, N1 Life aims to bridge the gap between laboratory discovery and real-world application, offering technology that is more efficient, dependable, and easier to translate into commercial products.

These platforms are designed to address challenges in skincare, dermatology, and therapeutic programs, including the targeted delivery of mRNA to specific organs or immune cells. By focusing on molecular design to navigate human tissue complexity, the company seeks to reduce development costs and improve the accessibility of novel treatments. Their work involves collaboration with academic researchers and the application of chemical science to solve unmet needs in pharmaceutical and cosmetic development, helping to advance promising science into measurable health outcomes and clinical solutions.